Sequana Medical NV
XBRU:SEQUA
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
0.58
4.8
|
| Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Sequana Medical NV
Sequana Medical NV
Cost of Revenue
Sequana Medical NV
Cost of Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Sequana Medical NV
XBRU:SEQUA
|
Cost of Revenue
-€4.1m
|
CAGR 3-Years
-26%
|
CAGR 5-Years
-27%
|
CAGR 10-Years
N/A
|
|
|
Nyxoah SA
XBRU:NYXH
|
Cost of Revenue
-€1.7m
|
CAGR 3-Years
-281%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Biocartis Group NV
XBRU:BCART
|
Cost of Revenue
-€29.5m
|
CAGR 3-Years
-11%
|
CAGR 5-Years
-19%
|
CAGR 10-Years
N/A
|
|
|
Ion Beam Applications SA
XBRU:IBAB
|
Cost of Revenue
-€294.3m
|
CAGR 3-Years
-19%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
N/A
|
|
Sequana Medical NV
Glance View
Sequana Medical NV is a commercial stage medical device company, which engages in the design, development, manufacture, and commercialization of medical device. The company is headquartered in Ghent, Oost-Vlaanderen and currently employs 60 full-time employees. The company went IPO on 2019-02-11. The firm focuses mainly on the development of treatment solutions for the management of liver disease, heart failure, malignant ascites and other fluid imbalance disorders. Sequana Medical NV provides alfapump, which is an implantable, programmable, wireless-charged and battery-powered system that is CE-marking for the management of refractory ascites due to liver cirrhosis and malignant ascites. Over 650 alfapump systems have been implanted. Apart from the Alfapump, the Company also aims to develop a direct sodium removal (DSR) therapy, which is a propriety approach to the treatment of volume overload in heart failure.
See Also
What is Sequana Medical NV's Cost of Revenue?
Cost of Revenue
-4.1m
EUR
Based on the financial report for Jun 30, 2024, Sequana Medical NV's Cost of Revenue amounts to -4.1m EUR.
What is Sequana Medical NV's Cost of Revenue growth rate?
Cost of Revenue CAGR 5Y
-27%
Over the last year, the Cost of Revenue growth was 4%. The average annual Cost of Revenue growth rates for Sequana Medical NV have been -26% over the past three years , -27% over the past five years .
You don't have any saved screeners yet
